First Light Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

First Light Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,184	Closed	-$2.02M	–	68
2015 Q4	$2.02M	Sell	10,184 -130	-1%	-$28.1K	0.85%	40
2015 Q3	$1.63M	Buy	+10,314	New	+$2.76M	0.8%	35

Other funds holding KPTI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Light Asset Management's KPTI Position: Q1 2016 in Review

First Light Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2016, closing a stake of 10,184 shares — an estimated $2.02M sold.

First Light Asset Management first reported a position in KPTI in Q3 2015 and held it in 2 quarters. The position peaked at $2.02M in Q4 2015. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2016.

First Light Asset Management reported no remaining Karyopharm Therapeutics position as of Q1 2016 after selling out during the quarter.
First Light Asset Management sold 10,184 Karyopharm Therapeutics shares in Q1 2016, an estimated $2.02M.
First Light Asset Management first reported a position in Karyopharm Therapeutics in Q3 2015 and held it in 2 quarters.
First Light Asset Management's Karyopharm Therapeutics position peaked at $2.02M in Q4 2015.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2016.

Based on First Light Asset Management's 13F filing for Q1 2016, filed 16 May 2016.